Ghose K, Carroll J D
Neuropsychobiology. 1984;12(2-3):122-6. doi: 10.1159/000118123.
In a double-blind crossover study, 8 patients with classical migraine received disulfiram (400 mg/day) for 6 days, alternating with matched placebo tablets at 2 weekly intervals. Intravenous dopamine and tyramine pressor tests were performed on the 3rd and 6th days of each phase, respectively. 50-75% of patients experienced migraine attacks within 24 h of a test. There was no difference in the incidence of attacks between dopamine and tyramine injections. The number of migraine-free days was more during the placebo week than during disulfiram treatment (p less than 0.05). The post-tyramine migraine index correlated directly with the amount of tyramine administered during the dose-response test (r = 0.66), but no such relationship was found with dopamine. In a further study, post-tyramine migraine was observed in only 1 of 5 patients treated with propranolol (80 mg/day) for 4 weeks. Neither disulfiram nor propranolol influenced the tyramine pressor sensitivity. It is concluded that increased adrenergic activity is responsible for more frequent attacks during disulfiram medication. A similar mechanism probably is responsible for post-dopamine/tyramine migraine in susceptible subjects. It is unlikely that tyramine plays any specific role, except via its effect on the adrenergic system, in the pathogenesis of migraine attacks. However, the tyramine challenge test can be useful in the evaluation of a putative antimigranous activity of a new drug.
在一项双盲交叉研究中,8例典型偏头痛患者接受双硫仑(400毫克/天)治疗6天,每2周交替服用匹配的安慰剂片。在每个阶段的第3天和第6天分别进行静脉注射多巴胺和酪胺升压试验。50 - 75%的患者在试验后24小时内出现偏头痛发作。多巴胺注射和酪胺注射之间的发作发生率没有差异。安慰剂周的无偏头痛天数比双硫仑治疗期间更多(p小于0.05)。酪胺激发试验后的偏头痛指数与剂量反应试验期间给予的酪胺量直接相关(r = 0.66),但与多巴胺未发现这种关系。在进一步的研究中,5例接受普萘洛尔(80毫克/天)治疗4周的患者中只有1例观察到酪胺激发试验后偏头痛。双硫仑和普萘洛尔均未影响酪胺升压敏感性。得出的结论是,肾上腺素能活性增加是双硫仑用药期间发作更频繁的原因。类似的机制可能是易感受试者中多巴胺/酪胺激发试验后偏头痛的原因。除了通过其对肾上腺素能系统的作用外,酪胺在偏头痛发作的发病机制中不太可能起任何特定作用。然而,酪胺激发试验可用于评估新药假定的抗偏头痛活性。